---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-21-000018"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T17:17:43.782493+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M

## Summary
- Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.
- Nucleic Acid Production revenue $192.5M (+532.8% YoY) driven by CleanCap demand for COVID-19 vaccines.
- Divested Protein Detection segment (Vector) for $124M cash to Thompson Street Capital Partners; close expected Q3 2021.
- 2021 revenue guidance raised to $745-770M from prior; reflects robust demand for Nucleic Acid Production.
- Facility expansions: new San Diego site to boost mRNA capacity; Biologic Safety Testing moving to larger Leland, NC site.

## SEC filing metadata
- accession: 0001823239-21-000018
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323921000018/0001823239-21-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323921000018/mrvi-20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-21-000018
- JSON: https://secwatch.observer/filing/0001823239-21-000018.json
- Plain text: https://secwatch.observer/filing/0001823239-21-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.